Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

ProMIS Neurosciences (PMN) Gets a Buy from Maxim Group

Tipranks - Tipranks - Wed Dec 24, 2025

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ProMIS Neurosciences, with a price target of $35.00. The company’s shares closed yesterday at $8.13.

Claim 70% Off TipRanks This Holiday Season

According to TipRanks, McCarthy is an analyst with an average return of -14.0% and a 33.40% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Plus Therapeutics, and SCYNEXIS.

Currently, the analyst consensus on ProMIS Neurosciences is a Strong Buy with an average price target of $19.33, which is a 137.76% upside from current levels. In a report released on December 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on ProMIS Neurosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.58 million. In comparison, last year the company had a net profit of $9.28 million

Read More on PMN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).